Advances in dual-targeted therapy for HER2-positive breast cancer based on trastu-zumab
10.3969/j.issn.1000-8179.2019.10.020
- VernacularTitle:以曲妥珠单抗为基础的HER-2阳性乳腺癌双靶向治疗进展
- Author:
Xinjuan LI
1
;
Hu MA
Author Information
1. 遵义医科大学附属医院胸部肿瘤科
- Keywords:
breast cancer;
human epidermal growth factor receptor 2 (HER-2);
trastuzumab;
dual-targeted therapy
- From:
Chinese Journal of Clinical Oncology
2019;46(10):533-536
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor (HER)-2-positive breast cancer is a type of highly invasive breast cancer with a high recurrence rate. Although the single-targeted treatment for HER-2 prolongs survival, patients still develop recurrence and metas-tasis. The mechanisms of dual-targeted therapies are non-overlapping and have synergistic effects, which further improves the survival of patients. Based on trastuzumab, this article reviews the current status and progression indual-targeted therapeutic regimens con-taining anti-HER-2.
